Hungarian pharma industry calls for more drug spending and fewer taxes

Following the re-election of Hungary’s Viktor Orbán as Prime Minister, the country’s leading pharma trade group has issued a summary of what it says are the most urgent priorities concerning the Hungarian pharmaceutical industry.

The Association of Innovative Pharmaceutical Manufacturers (AIPM) said it “welcomes the fact that financial resources increased during the last administrative cycle,” but warned that the administration should “proceed with a well-considered and forward-looking health policy.”

The AIPM said it would initiate negotiations immediately after the new government was installed, with the aim of tackling key issues including ensuring “access to the newest drug therapies.”